Published in Mol Cell Biol on October 01, 2000
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature (2007) 2.78
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Degradation of activated protein kinases by ubiquitination. Annu Rev Biochem (2009) 1.61
Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension (2009) 1.59
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discov (2015) 1.51
Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res (2001) 1.51
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A (2010) 1.38
Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol Biol Cell (2006) 1.37
Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci U S A (2006) 1.37
A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol (2010) 1.35
Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth. J Cell Biol (2005) 1.18
Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A (2005) 1.16
Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol (2010) 1.13
Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype. EMBO Rep (2005) 1.11
The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res (2008) 1.08
The regulation of embryo implantation and endometrial decidualization by progesterone receptor signaling. Mol Cell Endocrinol (2011) 1.07
Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3',5'-cyclic adenosine 5'-monophosphate inhibition of cyclin D1. Endocrinology (2009) 1.07
microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Res (2014) 1.07
The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res (2014) 1.06
Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev Cell (2012) 1.04
Mechanisms of ErbB receptor negative regulation and relevance in cancer. Exp Cell Res (2008) 0.99
Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. J Biol Chem (2009) 0.94
Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev (2013) 0.94
Gene 33/RALT is induced by hypoxia in cardiomyocytes, where it promotes cell death by suppressing phosphatidylinositol 3-kinase and extracellular signal-regulated kinase survival signaling. Mol Cell Biol (2006) 0.93
IBD candidate genes and intestinal barrier regulation. Inflamm Bowel Dis (2014) 0.92
Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development (2009) 0.90
PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget (2011) 0.89
Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo. Arthritis Res Ther (2013) 0.87
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS One (2013) 0.86
ERBB receptor feedback inhibitor 1 regulation of estrogen receptor activity is critical for uterine implantation in mice. Biol Reprod (2009) 0.85
Genome wide expression profiling reveals suppression of host defence responses during colonisation by Neisseria meningitides but not N. lactamica. PLoS One (2011) 0.84
MicroRNAs in the Myocyte Enhancer Factor 2 (MEF2)-regulated Gtl2-Dio3 Noncoding RNA Locus Promote Cardiomyocyte Proliferation by Targeting the Transcriptional Coactivator Cited2. J Biol Chem (2015) 0.83
Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field. Biomark Insights (2007) 0.82
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol (2015) 0.82
Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation. Mutagenesis (2014) 0.81
Gene expression modifications in Wharton's Jelly mesenchymal stem cells promoted by prolonged in vitro culturing. BMC Genomics (2013) 0.81
Chk1 phosphorylates the tumour suppressor Mig-6, regulating the activation of EGF signalling. EMBO J (2012) 0.81
Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes. Diabetologia (2014) 0.78
The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer. Oncotarget (2016) 0.77
ErbB2 dephosphorylation and anti-proliferative effects of neuregulin-1 in ErbB2-overexpressing cells; re-evaluation of their low-affinity interaction. Sci Rep (2013) 0.77
Amelioration of hypercholesterolemia by an EGFR tyrosine kinase inhibitor in mice with liver-specific knockout of Mig-6. PLoS One (2014) 0.77
Context-specific protection of TGFα null mice from osteoarthritis. Sci Rep (2016) 0.76
Inhibition of Cdc42 is essential for Mig-6 suppression of cell migration induced by EGF. Oncotarget (2016) 0.75
Fatty Liver and Insulin Resistance in the Liver-Specific Knockout Mice of Mitogen Inducible Gene-6. J Diabetes Res (2016) 0.75
Decreased Mitogen Inducible Gene 6 (MIG-6) Associated with Symptom Severity in Children with Autism. Biomark Insights (2014) 0.75
Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6. J Biol Chem (2016) 0.75
In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor. J Transl Med (2010) 0.75
Mig-6 gene knockout induces neointimal hyperplasia in the vascular smooth muscle cell. Dis Markers (2014) 0.75
Single-cell RNA sequencing reveals an altered gene expression pattern as a result of CRISPR/cas9-mediated deletion of Gene 33/Mig6 and chronic exposure to hexavalent chromium in human lung epithelial cells. Toxicol Appl Pharmacol (2017) 0.75
Nuclear Gene 33/Mig6 Regulates the DNA Damage Response through an ATM-dependent Mechanism. J Biol Chem (2017) 0.75
Milk's Role as an Epigenetic Regulator in Health and Disease. Diseases (2017) 0.75
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell (1995) 21.15
Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell (1993) 16.91
The structural basis for 14-3-3:phosphopeptide binding specificity. Cell (1997) 10.87
Signaling through scaffold, anchoring, and adaptor proteins. Science (1997) 9.48
PEST sequences and regulation by proteolysis. Trends Biochem Sci (1996) 8.90
The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science (1999) 7.60
The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature (1993) 7.11
MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell (1993) 6.55
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Control of EGF receptor signaling by clathrin-mediated endocytosis. Science (1996) 6.01
Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 5.91
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70
C. elegans cell-signalling gene sem-5 encodes a protein with SH2 and SH3 domains. Nature (1992) 5.59
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
Casein kinase 2: an 'eminence grise' in cellular regulation? Biochim Biophys Acta (1990) 4.51
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J (1987) 4.33
Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell (1995) 4.32
Protein-protein interactions define specificity in signal transduction. Genes Dev (2000) 3.62
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
Substrate specificity of protein kinase C. Use of synthetic peptides corresponding to physiological sites as probes for substrate recognition requirements. Eur J Biochem (1986) 3.37
Specificity within the EGF family/ErbB receptor family signaling network. Bioessays (1998) 3.37
Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J Biol Chem (1991) 3.37
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development (1997) 3.04
All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem (1996) 2.84
Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J (1999) 2.80
Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol (1999) 2.75
A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature (1993) 2.60
Sprouty, an intracellular inhibitor of Ras signaling. Cell (1999) 2.51
All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem (1989) 2.46
The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev (1998) 2.23
Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron (1999) 2.19
Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. EMBO J (1994) 2.19
Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature (1986) 2.15
Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol (1995) 2.13
Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (1998) 2.08
SH3 domains. Minding your p's and q's. Curr Biol (1995) 2.08
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'. Oncogene (1998) 1.91
ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol (1998) 1.88
Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem (1996) 1.88
The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes. Mol Cell Biol (1991) 1.82
Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J Cell Biol (1999) 1.80
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortex. Development (1997) 1.68
Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene (1997) 1.64
Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem (1998) 1.62
Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts. J Biol Chem (1999) 1.57
Effect of epidermal growth factor receptor internalization on regulation of the phospholipase C-gamma1 signaling pathway. J Biol Chem (1999) 1.57
Cloning and characterization of a novel Cdc42-associated tyrosine kinase, ACK-2, from bovine brain. J Biol Chem (1997) 1.54
The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol (1990) 1.52
The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene (1994) 1.51
Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. Proc Natl Acad Sci U S A (2000) 1.50
The transmembrane molecule kekkon 1 acts in a feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis. Cell (1999) 1.50
Shc products are substrates of erbB-2 kinase. Oncogene (1993) 1.46
Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol (1988) 1.42
Receptor signaling: when dimerization is not enough. Curr Biol (1999) 1.42
Negative feedback mechanisms and their roles during pattern formation. Cell (1999) 1.37
The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol Cell Biol (1991) 1.36
Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol (1996) 1.36
Synthetic peptides corresponding to the site phosphorylated in 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as substrates of cyclic nucleotide-dependent protein kinases. J Biol Chem (1986) 1.34
The role of autophosphorylation in modulation of erbB-2 transforming function. New Biol (1990) 1.33
Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J (1999) 1.33
Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol (1998) 1.30
Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway. Mol Cell (1998) 1.19
Mona, a novel hematopoietic-specific adaptor interacting with the macrophage colony-stimulating factor receptor, is implicated in monocyte/macrophage development. EMBO J (1998) 1.17
Src-like adaptor protein (Slap) is a negative regulator of mitogenesis. Curr Biol (1998) 1.13
Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation. Exp Cell Res (1995) 1.09
An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. Mol Cell Biol (1994) 1.07
Quantitative variations in the level of MAPK activity control patterning of the embryonic termini in Drosophila. Dev Biol (1999) 1.07
Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene (1995) 1.02
The juxtamembrane regions of the epidermal growth factor receptor and gp185erbB-2 determine the specificity of signal transduction. Mol Cell Biol (1991) 0.98
The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases. Oncogene (1999) 0.96
Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. Proc Natl Acad Sci U S A (1996) 0.94
Surface distribution and internalization of erbB-2 proteins. Exp Cell Res (1992) 0.92
Rat gene 33: analysis of its structure, messenger RNA and basal promoter activity. Nucleic Acids Res (1989) 0.88
Molecular cloning and analysis of full-length cDNAs cognate to a rat gene under multihormonal control. Arch Biochem Biophys (1989) 0.80
Transformation of NIH3T3 cells by Rous sarcoma virus occurs with high efficiency in the absence of proviral rearrangements or amplification. Oncogene (1992) 0.76
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J (2001) 5.29
White collar-1, a central regulator of blue light responses in Neurospora, is a zinc finger protein. EMBO J (1996) 2.71
Development of a highly efficient expression cDNA cloning system: application to oncogene isolation. Proc Natl Acad Sci U S A (1991) 2.48
Differentiation of PC12 phaeochromocytoma cells induced by v-src oncogene. Nature (1985) 2.19
EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science (1990) 1.76
In vitro catenation and decatenation of DNA and a novel eucaryotic ATP-dependent topoisomerase. Cell (1980) 1.76
Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res (1989) 1.73
Complex genetic control of HDL levels in mice in response to an atherogenic diet. Coordinate regulation of HDL levels and bile acid metabolism. J Clin Invest (1997) 1.67
Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci U S A (2001) 1.63
Roles in dimerization and blue light photoresponse of the PAS and LOV domains of Neurospora crassa white collar proteins. Mol Microbiol (1998) 1.62
Distinctive effects of the viral oncogenes myc, erb, fps, and src on the differentiation program of quail myogenic cells. Proc Natl Acad Sci U S A (1985) 1.61
Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene (2003) 1.60
Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res (1997) 1.58
Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage (1996) 1.57
The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol (1990) 1.52
Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. J Gastroenterol (1999) 1.44
High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest (1998) 1.43
The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol (1990) 1.42
Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur J Gastroenterol Hepatol (1997) 1.42
Template supercoiling by a chimera of yeast GAL4 protein and phage T7 RNA polymerase. Science (1990) 1.41
Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J Immunol (1998) 1.37
Prevalence and risk factors for nosocomial infections in hospitals of the Veneto region, north-eastern Italy. Infection (2008) 1.37
The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol Cell Biol (1991) 1.36
Transplantation of chondrocytes seeded on a hyaluronan derivative (hyaff-11) into cartilage defects in rabbits. Biomaterials (2001) 1.35
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet (1996) 1.35
Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood (1997) 1.34
The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene (2007) 1.33
Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue-specific genes by separable mechanisms. Mol Cell Biol (1996) 1.33
Reconstitution of cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle. Mol Cell Biol (2001) 1.32
Identification of a calcium-binding, brain specific protein in the axoplasm of squid giant axons. J Neurochem (1973) 1.24
Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer (1992) 1.24
Constitutive phosphorylation of Shc proteins in human tumors. Oncogene (1995) 1.23
Terminally differentiated skeletal myotubes are not confined to G0 but can enter G1 upon growth factor stimulation. Cell Growth Differ (1996) 1.23
Identification of the cis-elements mediating the autogenous control of ribosomal protein L2 mRNA stability in yeast. EMBO J (1995) 1.22
Comparative mutational analysis of wild-type and stretched tRNA3(Leu) gene promoters. Proc Natl Acad Sci U S A (1987) 1.21
Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Mol Pharmacol (1999) 1.17
Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol (1996) 1.15
Separation of RNA transcription and processing activities from X. laevis germinal vesicles. Cell (1979) 1.14
Identification and biochemical characterization of novel putative substrates for the epidermal growth factor receptor kinase. J Biol Chem (1992) 1.13
Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics (1984) 1.12
Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage. Carcinogenesis (1999) 1.11
pH-dependent prion protein conformation in classical Creutzfeldt-Jakob disease. J Biol Chem (2001) 1.10
Dispositions of junctional feet in muscles of invertebrates. J Muscle Res Cell Motil (1992) 1.09
The WRN and MUS81 proteins limit cell death and genome instability following oncogene activation. Oncogene (2012) 1.07
Molecular dissection of a protein SopB essential for Escherichia coli F plasmid partition. J Biol Chem (1996) 1.07
Distinct effects of Rac1 on differentiation of primary avian myoblasts. Mol Biol Cell (1999) 1.07
Interaction with normal cells suppresses the transformed phenotype of v-myc-transformed quail muscle cells. Cell (1989) 1.06
Myosin rod phosphorylation and the catch state of molluscan muscles. Science (1987) 1.05
The neuronal alpha6 subunit forms functional heteromeric acetylcholine receptors in human transfected cells. Eur J Neurosci (1998) 1.05
Critical comparison of nine different self-administered questionnaires for the evaluation of disability caused by low back pain. Eura Medicophys (2005) 1.05
p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene (1997) 1.05
Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene (1995) 1.02
Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med (2001) 1.02
Dimer ribbons in the three-dimensional structure of sarcoplasmic reticulum. J Mol Biol (1985) 1.02
A PKC-eta/Fyn-dependent pathway leading to keratinocyte growth arrest and differentiation. Mol Cell (2000) 1.01
Black widow spider toxin-induced calcium fluxes and transmitter release in a neurosecretory cell line. Nature (1980) 1.00
SDF-1alpha-mediated modulation of synaptic transmission in rat cerebellum. Eur J Neurosci (2000) 0.99
Eps8, a tyrosine kinase substrate, is recruited to the cell cortex and dynamic F-actin upon cytoskeleton remodeling. Exp Cell Res (1998) 0.99
Mini-titins in striated and smooth molluscan muscles: structure, location and immunological crossreactivity. J Muscle Res Cell Motil (1993) 0.99
Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. Int J Cancer (2000) 0.98
Alpha 5 subunit forms functional alpha 3 beta 4 alpha 5 nAChRs in transfected human cells. Neuroreport (1997) 0.98
Defective actin polymerization in EBV-transformed B-cell lines from patients with the Wiskott-Aldrich syndrome. J Pathol (1998) 0.98
Transcription of muscle-specific genes is repressed by reactivation of pp60v-src in postmitotic quail myotubes. Mol Cell Biol (1991) 0.96
Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim Biophys Acta (1998) 0.96
E2F activates late-G1 events but cannot replace E1A in inducing S phase in terminally differentiated skeletal muscle cells. Oncogene (1999) 0.95
Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother (2001) 0.95
Nerve growth factor potentiates actomyosin adenosinetriphosphatase. Proc Natl Acad Sci U S A (1978) 0.95
Crystalline structure of sarcoplasmic reticulum from scallop. J Cell Biol (1983) 0.95
Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene (1995) 0.95
Functional properties of neuronal nicotinic acetylcholine receptor channels expressed in transfected human cells. Eur J Neurosci (1997) 0.95
Percutaneous stenting of the internal carotid artery: the European CAST I Study. Carotid Artery Stent Trial. J Endovasc Surg (1999) 0.95
Outcome after discontinuation of antiepileptic drug therapy in children with epilepsy. Epilepsia (1989) 0.95
Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol Cell Biol (1996) 0.94
Identification of a determinant of acetylcholine receptor gating kinetics in the extracellular portion of the gamma subunit. Eur J Neurosci (1996) 0.94
Variant of ataxia-telangiectasia with low-level radiosensitivity. Hum Genet (1985) 0.93
Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res (1989) 0.93
Painless intussusception and altered mental status. Am J Emerg Med (1999) 0.93
Negative regulation of receptor tyrosine kinase signals. FEBS Lett (2001) 0.93
Phenotypically immature IgG-bearing B cells in patients with hypogammaglobulinemia. J Clin Immunol (1986) 0.92
Power spectrum analysis contribution to the detection of cardiovascular dysautonomia in multiple sclerosis. Acta Neurol Scand (1996) 0.92
Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia. Genes Immun (2007) 0.92
The mechanism of action of nerve growth factor. Annu Rev Pharmacol Toxicol (1991) 0.92
A PCR-based non-radioactive X-chromosome inactivation assay for genetic counseling in X-linked primary immunodeficiencies. Life Sci (1997) 0.92
The human transforming growth factor type alpha coding sequence is not a direct-acting oncogene when overexpressed in NIH 3T3 cells. Proc Natl Acad Sci U S A (1987) 0.92
p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Differ (2004) 0.92
Development of 'revertant' myotubes in cultures of Rous sarcoma virus transformed avian myogenic cells. Differentiation (1983) 0.91
DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity. Cell Death Differ (2012) 0.90
Ordered arrays of Ca2+-ATPase on the cytoplasmic surface of isolated sarcoplasmic reticulum. Biophys J (1985) 0.90
X-ray absorption near edge structure (XANES) determination of calcium sites of troponin C and parvalbumin. J Mol Biol (1983) 0.90
The v-myc oncogene is sufficient to induce growth transformation of chick neuroretina cells. Nature (1987) 0.90
Topoisomerase II forms multimers in vitro: effects of metals, beta-glycerophosphate, and phosphorylation of its C-terminal domain. Mol Cell Biol (1994) 0.90
Rod phosphorylation favors folding in a catch muscle myosin. Proc Natl Acad Sci U S A (1987) 0.90
Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes. Leukemia (2006) 0.90
Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression. Leukemia (2012) 0.89
Impaired glutathione reductase activity and levels of collagenase and elastase in synovial fluid in rheumatoid arthritis. Clin Exp Rheumatol (2003) 0.89